TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Energy/Fatigue' Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Response times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I/T Ratio (Immature/Total Immature Neutrophil)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Negative Blood Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of Diarrhea (Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of lung function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of glycosilated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: parental mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Titer level of Rabies Virus Neutralizing Antibody (RVNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in brain function for selective attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in stress physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in child school performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-sitting sympathetic nervous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gln/Glu ratio following the first ECT treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of morphine until pain < 4 on the NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to finish a long distance triathlon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Carpal Tunnel Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to progression by PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroesophageal regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of headache-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Through 24 Hours Postdose in Population-Corrected QT (QTcP) Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration (Cmax) of LY3009104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve From Time 0 to Infinity [AUC(0-inf)] of LY3009104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 1 or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with antigen loss (HBeAg and HBsAg loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatocellular carcinoma (HCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PrEP Eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PrEP Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oral morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of PORT-A-CATH® related events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Lipid Rich Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall incidence of bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: 6-Month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Disclosure to child of child's HIV-positive status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Flow cytometric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Treatment Administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: One-year Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: MRI-estimated tumour volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of Opioids Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Symptom Score of the WURSS-21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective assessment of dry eye syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical specificity and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of latex allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Ablation of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of successful anterior capsulotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful corneal Incisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful phacofragmentation as intended
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Satisfaction with Medical Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of primary and recurrent BCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the distal esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Scar improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total volume of new cerebral lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: safety and efficacy of thalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phosphorylation of S6K, 4E-BP-1 and AMPK
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With HI Titers ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Seroconversion or Significant Increase in HI Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TAS2R38 genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAS2R38 mRNA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciliary beat frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rx Pill Count
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of rBV A/B
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression, Anxiety, Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dP/dt max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-HAV titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Urine BPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall survival distribution
Endpoint domain: Mortality/survival
Primary endpoint: QT/Corrected QT (QTc) Interval Prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of FcRn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects to Exhibit Adrenal Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma Concentration of HBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Pain Scale (Describing Worst Pain Felt During the Past Week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Function by Lower Extremity Functional Scale Report Form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in lesion texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of organoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical influenza by self-reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza virus infection confirmed by RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusive and hydrating capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety score
Endpoint domain: Adverse events/effects
Primary endpoint: loss of skeletal muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Functional Capacity (400 meters walk test)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Client Oriented Scale of Improvement (COSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing Handicap Inventory of the Elderly (HHIE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: International Outcome Inventory for Hearing Aids (IOI-HA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Freezing of Gait Questionnaire (FOG-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success or failure for patients in late stage HAT
Endpoint domain: Mortality/survival
Primary endpoint: Lymph node-level concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in knee motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in depressed mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in perceived spousal support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: reduction in HAMD total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color assessment of facial hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment of facial hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Global Assessment of facial hyperpigmentation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluate side effects of Isobutylamido-thiazolyl-resorcinol cream 0.2% or vehicle cream
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants Who Had an Additional Inpatient Detoxification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Ischemic Cardiovascular Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung herniation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 500 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of clinically cured patients at the third month after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with epithelialized lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of gene polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity at far distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-extra cerebral arteries vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Headache score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: locoregional recurrence-free interval
Endpoint domain: Mortality/survival
Primary endpoint: UPDRS motor score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: UPDRS total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TMAO biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first occurrence of a major cardiovascular disease event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in cholesterol at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in HDL at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in LDL at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in triglycerides at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in VLDL at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: percent stenosis of Study Vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: composite of total mortality, stroke, MI, or coronary revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Child egg consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child minimum dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Respiratory muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Motion visual evoked potential (mVEPs) asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optokinetic nystagmus (OKN) asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Motion Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Failure of First Line Therapy or Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced Immunological Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Experienced Clinical Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change scores of Modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change scores of Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) Pain on Weight Bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) for Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to worsening of disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute graft injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Denver-II Developmental Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alberta Infant Motor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelium-dependent flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of volunteers with moderate or greater reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Scale of Prodromal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in hypoglycemic ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in arachidonic acid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hip abductor muscles neuro-physiological state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of complete and incomplete blinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Experienced Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants That Experienced Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants That Experienced Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants That Experienced Transient Ischemic Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants That Experienced Myocardial Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants That Experienced Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Observational Score Behavioral Distress Revised (OSBD-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fetal heart rate tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Brain Derived Neurotrophic Factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in BDNF signaling pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medial AP Translations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral AP Translations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Society Knee Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Date of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Low-density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall pain score during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone to plasma ratio for Debio 1452
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes